The Project

AlphaSyn

About Us

The deposition of protein inclusions in the brain, as a result of protein misfolding and aggregation is a common feature of various neurodegenerative diseases, such as Alzheimer’s disease. The same phenomenon is also observed in PD, characterized by the accumulation of aggregated forms of the presynaptic protein α-synuclein (aSyn) in the brain. Studies have shown that aggregated forms of aSyn are particularly toxic to neuronal cells. These neurotoxic aggregates may be smaller in size (oligomers) or larger (fibrils). Recent studies have shown that oligomers and small aggregates of aSyn are the most neurotoxic protein species and contribute the most to the pathogenicity of the disease. Consequently, inhibiting the formation of αSyn neurotoxic oligomers/aggregates would restrict the disease progression in the early stages, where the pathology is relatively localized and therefore more susceptible to therapeutic regimens.

AlphaSyn

The Project

In the framework of the AlphaSyn project, we will develop new and effective small molecule aSyn aggregation inhibitors. These will result from screening (1) combinatorial libraries of cyclic oligopeptides comprising hundreds of millions of different molecules, and (2) natural product libraries from Greek marine organisms. The most effective inhibitors of αSyn aggregation and neurotoxicity will be preclinically developed with the ultimate goal of developing and exploiting commercially (1) a neuroprotective nutritional supplement that promotes the kinetic and cognitive function of elderly people, as well as (2) lead compounds with potentially therapeutic properties against PD.